echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Children with diabetes usher in the first weekly GLP-1 receptor agonist therapy

    Children with diabetes usher in the first weekly GLP-1 receptor agonist therapy

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 23, 2021, AstraZeneca announced that the U.


    Since the mid-1990s, the incidence of type 2 diabetes has been increasing among children and adolescents


    In October 2017, the FDA approved Exenatide as a single-dose automatic injection device administered once a week for the treatment of adult patients with type 2 diabetes


    This approval is supported by the results of a 24-week, randomized, double-blind, placebo-controlled Phase 3 clinical trial called BCB114


    In terms of safety, the safety and tolerability characteristics observed in the trial are similar to those observed in adults


    Reference materials:

    [1] BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.